Aethlon Medical INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Aethlon Medical, Inc. announced amendments to its Pre-Funded Warrants, making them immediately exercisable, while still seeking shareholder approval for Nasdaq compliance.
NASDAQ
Aethlon Medical reports positive safety data and exploratory findings from its Australian oncology trial, advancing to the second cohort, while seeking shareholder approval for significant share authorization increases and warrant exercises to fund ongoing operations.
NASDAQ
Aethlon Medical is holding a special meeting to seek stockholder approval for a reverse stock split and the issuance of shares related to inducement warrants.
NASDAQ
Aethlon Medical is holding its annual shareholder meeting on September 27, 2024, to vote on director elections, auditor ratification, an equity incentive plan amendment, executive compensation, and meeting adjournment if needed.
NASDAQ
Aethlon Medical is holding its annual stockholder meeting on September 27, 2024, to vote on director elections, auditor ratification, an equity incentive plan amendment, executive compensation, and meeting adjournment.